Biotech Firm Omega Therapeutics OK'd For $14M Ch. 11 Sale
Biotechnology developer Omega Therapeutics received a Delaware bankruptcy judge's approval Wednesday to sell itself to its debtor-in-possession lender and a major shareholder for $14 million in Chapter 11....To view the full article, register now.
Already a subscriber? Click here to view full article